Windlas Biotech Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Highlight Improved Price Attractiveness

Windlas Biotech’s current P/E ratio stands at 23.34, a figure that positions it favourably against key competitors in the Pharmaceuticals & Biotechnology sector. For context, Ajanta Pharma trades at a P/E of 36.73, Gland Pharma at 31.82, and J B Chemicals & Pharmaceuticals at 43.69, all of which are classified as expensive or very expensive by market standards. This comparatively lower P/E suggests that Windlas Biotech’s shares are trading at a discount relative to earnings, enhancing their appeal for value-conscious investors.

Similarly, the company’s price-to-book value ratio of 2.92 further underscores this valuation attractiveness. While not the lowest in the sector, it remains below levels seen in many peers, signalling a more reasonable price relative to the company’s net asset base. This is particularly relevant given Windlas Biotech’s robust return on capital employed (ROCE) of 24.60% and return on equity (ROE) of 12.60%, which indicate efficient utilisation of capital and shareholder funds.

Comparative Enterprise Value Multiples Reinforce Relative Value

Examining enterprise value (EV) multiples, Windlas Biotech’s EV to EBITDA ratio is 12.65, markedly lower than sector heavyweights such as Wockhardt at 46.18 and AstraZeneca Pharma at 74.79. This suggests that the market is valuing Windlas Biotech’s operating cash flows more conservatively, potentially reflecting concerns over near-term growth or sector headwinds. However, for investors seeking exposure to the pharmaceutical space at a more reasonable valuation, this could represent an opportunity.

The EV to EBIT multiple of 17.97 and EV to capital employed ratio of 4.36 also support the narrative of relative undervaluation. These metrics, when viewed alongside the company’s dividend yield of 0.78%, provide a comprehensive picture of Windlas Biotech’s current market standing: a stock that offers operational efficiency and moderate income potential at a valuation discount.

Mojo Grade Downgrade Reflects Broader Market Sentiment

Despite the improved valuation parameters, Windlas Biotech’s Mojo Grade was downgraded from Hold to Sell on 4 February 2026, with a current Mojo Score of 37.0. This downgrade signals caution from analysts, likely driven by recent price performance and sector dynamics. The stock has declined 2.54% on the day of reporting, closing at ₹739.20, down from a previous close of ₹758.50. Its 52-week high remains at ₹1,137.60, while the 52-week low is ₹728.15, indicating a significant retracement from peak levels.

Performance comparisons with the Sensex reveal mixed results. Over the past week, Windlas Biotech’s stock fell 2.25%, slightly outperforming the Sensex’s 2.91% decline. However, over the past month, the stock’s 13.39% drop considerably underperformed the Sensex’s 5.58% fall. Year-to-date, the stock is down 7.02%, roughly in line with the Sensex’s 7.39% decline. Over a one-year horizon, Windlas Biotech has underperformed significantly with a 17.98% loss, while the Sensex gained 6.16%. Longer-term returns remain impressive, with a three-year gain of 193.16% compared to the Sensex’s 31.04%, highlighting the stock’s strong historical growth trajectory.

Sector Peer Valuations Emphasise Windlas Biotech’s Relative Appeal

Within the Pharmaceuticals & Biotechnology sector, Windlas Biotech’s valuation stands out as attractive when juxtaposed with peers. Ajanta Pharma, Gland Pharma, Emcure Pharma, Pfizer, Sai Life Sciences, Wockhardt, AstraZeneca Pharma, and ERIS Lifesciences all carry expensive or very expensive tags, with P/E ratios ranging from 29.05 to 165.08 and EV to EBITDA multiples often exceeding 15. This premium pricing reflects expectations of stronger growth, larger market capitalisations, or superior earnings quality.

Windlas Biotech’s PEG ratio of 3.22 is higher than some peers like Gland Pharma (1.4) and Wockhardt (0.99), indicating that while the stock is attractively priced on absolute multiples, growth expectations relative to earnings may be more modest. Investors should weigh this alongside the company’s solid ROCE and ROE metrics, which suggest operational strength despite valuation conservatism.

Investment Implications and Outlook

Windlas Biotech’s shift to an attractive valuation grade offers a compelling case for investors seeking exposure to the pharmaceuticals and biotechnology sector at a more reasonable price point. The company’s strong capital efficiency, as evidenced by its ROCE of 24.60%, and respectable ROE of 12.60%, underpin its operational quality. However, the downgrade in Mojo Grade to Sell and recent price weakness highlight ongoing risks, including sector volatility and competitive pressures.

Investors should consider Windlas Biotech’s valuation in the context of its growth prospects and peer comparisons. While the stock trades at a discount to many large-cap peers, its PEG ratio suggests growth expectations are moderate. The stock’s dividend yield of 0.78% adds a modest income component but is unlikely to be a primary attraction.

Given the mixed signals, a cautious approach may be warranted. Value investors might find the current price levels attractive for accumulation, particularly if the company can sustain or improve its operational metrics. Conversely, those prioritising growth or momentum may prefer to explore alternatives within the sector or broader market.

Historical Performance Contextualises Current Valuation

Windlas Biotech’s long-term performance remains impressive, with a three-year return of 193.16% far outpacing the Sensex’s 31.04% gain. This strong historical growth supports the argument that the company has delivered substantial value creation over time. However, the recent underperformance over one year and year-to-date periods signals caution, as market sentiment has turned more cautious amid broader economic and sector-specific challenges.

Price volatility is evident in the stock’s 52-week range, with a high of ₹1,137.60 and a low of ₹728.15. The current price near the lower end of this range may attract bargain hunters but also reflects the need for careful analysis of catalysts that could drive a sustained recovery.

Conclusion

Windlas Biotech Ltd’s valuation parameters have shifted favourably, presenting an attractive entry point relative to peers and historical norms. The company’s efficient capital utilisation and reasonable multiples contrast with the broader sector’s expensive valuations. Nonetheless, the downgrade in overall rating and recent price declines caution investors to weigh risks carefully. For those with a value-oriented investment horizon, Windlas Biotech offers a potentially rewarding opportunity, provided sector headwinds and company-specific challenges are monitored closely.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today